Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odesivimab
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Odesivimab is a fully humanized IgG1κ monoclonal antibody that targets the glycoprotein (GP) on the surface of Zaire ebolavirus. It is used exclusively in combination with two other monoclonal antibodies, atoltivimab and maftivimab, as part of a fixed-dose regimen marketed under the brand name Inmazeb. The mechanism of action involves binding to distinct sites on the Ebola virus GP, thereby blocking viral attachment and entry into host cells and facilitating immune-mediated neutralization. Odesivimab is indicated for the treatment of infections caused by Zaire ebolavirus in adults and children, including neonates born to infected mothers[2][5][8]. The drug was developed by Regeneron Pharmaceuticals.
- Brand names
- Inmazeb
- Other names
- odesivimab-ebgn
02
Targets
PYG (Glycogen phosphorylase)
Beyond the preview
Go deeper on odesivimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odesivimab.